TENAX THERAPEUTICS, INC. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- TENAX THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2026-06-30 was $13.34M, a 4733.33% increase year-over-year.
- TENAX THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2026-03-31 was $30.42M, a 8665.42% increase year-over-year.
- TENAX THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2025-09-30 was $3.06M.
- TENAX THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2025-06-30 was $276.00K.
- TENAX THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2025 was $15.29M, a 22379.41% increase from fiscal 2024.
- TENAX THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2024 was $68.00K.
- TENAX THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- TENAX THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2013 was $4.51M, a 30.26% increase from fiscal 2012.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2026-06-30 | $13.34M 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $30.42M 10-Q · filed 2026-07-31 | |
| 2025-12-31 | $15.29M 10-K · filed 2026-03-10 | |
| 2025-09-30 | $3.06M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $276.00K 10-Q · filed 2026-07-31 | |
| 2025-03-31 | $347.00K 10-Q · filed 2026-07-31 | |
| 2024-12-31 | $68.00K 10-K · filed 2026-03-10 | |
| 2014-04-30 | $0.00 10-K · filed 2017-03-16 | |
| 2013-04-30 | $4.51M 10-KT · filed 2016-03-14 | |
| 2012-04-30 | $3.46M 10-K · filed 2013-06-26 | |
| 2011-04-30 | $8.71K 10-K · filed 2012-07-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |